These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 16434381

  • 1. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P, French Study Group on Sickle Cell Disease.
    Haematologica; 2006 Jan; 91(1):125-8. PubMed ID: 16434381
    [Abstract] [Full Text] [Related]

  • 2. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
    Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R.
    Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
    [Abstract] [Full Text] [Related]

  • 3. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F, Bejaoui M.
    Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
    [Abstract] [Full Text] [Related]

  • 4. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [Abstract] [Full Text] [Related]

  • 5. [Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety].
    de Montalembert M.
    Transfus Clin Biol; 2008 Dec; 15(1-2):34-8. PubMed ID: 18499496
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
    Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP.
    Pediatr Blood Cancer; 2006 Dec; 47(7):894-900. PubMed ID: 16526051
    [Abstract] [Full Text] [Related]

  • 7. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH.
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [Abstract] [Full Text] [Related]

  • 8. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A, Jerrell JM, Stallworth JR.
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [Abstract] [Full Text] [Related]

  • 9. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.
    Dahoui HA, Hayek MN, Nietert PJ, Arabi MT, Muwakkit SA, Saab RH, Bissar AN, Jumaa NM, Farhat FS, Dabbous IA, Bitar FF, Abboud MR.
    Pediatr Blood Cancer; 2010 Mar; 54(3):398-402. PubMed ID: 19827138
    [Abstract] [Full Text] [Related]

  • 10. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A, de Bisotti R, Sumoza D, Fairbanks V.
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [Abstract] [Full Text] [Related]

  • 11. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
    Nzouakou R, Bachir D, Lavaud A, Habibi A, Lee K, Lionnet F, Hulin A, Jouault H, Préhu C, Roudot-Thoraval F, Girot R, Galactéros F.
    Acta Haematol; 2011 Nov; 125(3):145-52. PubMed ID: 21196716
    [Abstract] [Full Text] [Related]

  • 12. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Nov; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcome.
    Brachet C, Azzi N, Demulder A, Devalck C, Gourdin A, Gulbis B, Klein A, Le PQ, Loop M, Sariban E, Ferster A.
    Bone Marrow Transplant; 2004 Apr; 33(8):799-803. PubMed ID: 14767501
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow transplantation or hydroxyurea for sickle cell anemia: long-term effects on semen variables and hormone profiles.
    Lukusa AK, Vermylen C, Vanabelle B, Curaba M, Brichard B, Chantrain C, Dupont S, Ferrant A, Wyns C.
    Pediatr Hematol Oncol; 2009 Jun; 26(4):186-94. PubMed ID: 19437321
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH, Al-Dabbous IA.
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [Abstract] [Full Text] [Related]

  • 16. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
    Akar NA, Adekile A.
    Med Princ Pract; 2008 Mar; 17(5):404-8. PubMed ID: 18685282
    [Abstract] [Full Text] [Related]

  • 17. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B, Neonato MG, Girot R, Aractingi S.
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [Abstract] [Full Text] [Related]

  • 18. Hydroxyurea for children with sickle cell disease.
    Heeney MM, Ware RE.
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [Abstract] [Full Text] [Related]

  • 19. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A, Gumruk F, Gurgey A.
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [Abstract] [Full Text] [Related]

  • 20. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.
    Puffer E, Schatz J, Roberts CW.
    Child Neuropsychol; 2007 Mar; 13(2):142-54. PubMed ID: 17364571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.